课题基金 / 基金详情

Study for therapeutic strategy using the target protein expressionsystem based on protein stabilization/destabilization in the cancertracing mechanism

Study for therapeutic strategy using the target protein expressionsystem based on protein stabilization/destabilization in the cancertracing mechanism
癌症追踪机制中基于蛋白质稳定/去稳定的靶蛋白表达系统的治疗策略研究
批准号:
23659880
负责人:
SAKAI Hidetaka
金额:
$2.33万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Challenging Exploratory Research
财政年份:
2011
资助国家:
日本
项目状态:
已结题
起止时间:
2011 至 2012

项目摘要

项目成果

SAKAI Hidetaka的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
We studied regulations of gene/protein expression in oral squamous cell carcinoma (OSCC) cells stimulated by exogenous factors and drug-resistance of the OSCC cells in order to develop the anti-cancer therapeutic strategy using the target protein expression system based on protein stabilization/destabilization in the cancer tracing mechanism. The OSCC cells downregulated the keratinocyte differentiation-related genes and upregulated the expression of SERPINB3/4 (SCCA1/2), well-known SCC markers, following treatment with IL-22. These results indicate that IL-22 and IL-6 differentially activate the STAT-signalingpathway depending on the type of OSCC. When the OSCC cells with resistance to the V-ATPase inhibitor were treated with combination with SAHA, these cells indicated the change in STAT signaling pathway and became more susceptible to the V-ATPase inhibitor. Together these findings suggest V-ATPase could be an attractive target against OSCCs. In addition, combination with other reagents such as SAHA could help V-ATPase inhibitors to induce apoptosis in the V-ATPase inhibitor-resistant OSCC cells via change in STAT-signal pathway. Together, the regulation of STAT-signaling pathway may be a pivotal target for development of the tumor specific expression system. The accumulation of these data could lead to the development of new perspectives on this disease, and potentially new therapies with few side effects, thereby improving the treatment of patients with OSCC
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
V-ATPase阻害剤Concanamycin Aによる口腔扁平上皮の細胞死誘導について
V-ATP酶抑制剂刀那霉素A诱导口腔鳞状上皮细胞死亡
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [吉田寿人, 清島保, 永田健吾, 和田裕子, 藤原弘明, 坂井英隆]
通讯作者: 坂井英隆
DOI: --
发表时间: 2011
期刊:
影响因子: --
作者: [小林家吉, 清島保, 永田健吾, 和田裕子, 藤原弘明, 坂井英隆]
通讯作者: 坂井英隆
Parotid gland myoepithelioma with remarkable cystic formation: A case report.
具有显着囊性形成的腮腺肌上皮瘤:病例报告。
DOI: 10.1016/j.ajoms.2012.05.018
发表时间: 2013
期刊: J. Oral Maxillofac. Surg. Med. Pathol.
影响因子: --
作者: [Kakehashi H., Kawano S., Kiyoshima T., Shimizu M., Moriyama M., Matsubara R., Kiyosue T., Goto Y., Shiratsuchi H., Nakamura S.]
通讯作者: Nakamura S.
Netrin-1結合部位欠失DCC遺伝子導入による癌細胞のアポトーシス誘導
通过引入缺乏 Netrin-1 结合位点的 DCC 基因诱导癌细胞凋亡
DOI: --
发表时间: 2012
期刊:
影响因子: --
作者: [和田裕子, 清島保, 小林家吉, 永田健吾, 藤原弘明, 塩塚真帆, 坂井英隆]
通讯作者: 坂井英隆
18
    Research of integrable systems around the Painleve equations
    • 批准号:
      15K04894
    • 项目类别:
      Grant-in-Aid for Scientific Research (C)
    • 资助金额:
      $2.75万
    • 财政年份:
      2015
    • 负责人:
      SAKAI Hidetaka
    • 依托单位:
    Study on integrable systems around the Painleve systems
    • 批准号:
      20740089
    • 项目类别:
      Grant-in-Aid for Young Scientists (B)
    • 资助金额:
      $2.66万
    • 财政年份:
      2008
    • 负责人:
      SAKAI Hidetaka
    • 依托单位:
    Functional analysis for molecular interaction through a new member of the immunoglobulin superfamily in tooth germ development
    • 批准号:
      20390466
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $12.31万
    • 财政年份:
      2008
    • 负责人:
      SAKAI Hidetaka
    • 依托单位:
    FUNCTIONAL ANALYSIS OF TOOTH GERM DEVELOPMENT-RELATED GENES
    • 批准号:
      13470384
    • 项目类别:
      Grant-in-Aid for Scientific Research (B)
    • 资助金额:
      $9.15万
    • 财政年份:
      2001
    • 负责人:
      SAKAI Hidetaka
    • 依托单位: